Functional systemic CD4 immunity is required for clinical responses to PD-L1/PD-1 blockade therapy.
Zuazo M, Arasanz H, Fernández-Hinojal G, García-Granda MJ, Gato M, Bocanegra A, Martínez M, Hernández B, Teijeira L, Morilla I, Lecumberri MJ, Fernández de Lascoiti A, Vera R, Kochan G, Escors D.
Zuazo M, et al. Among authors: escors d.
EMBO Mol Med. 2019 Jul;11(7):e10293. doi: 10.15252/emmm.201910293. Epub 2019 Jun 6.
EMBO Mol Med. 2019.
PMID: 31273938
Free PMC article.